EU green light for Zogenix’s Fintepla
Oral solution approved to treat seizures associated with Dravet syndrome
Read More
Tag: Fintepla
FDA refuses Zogenix’s seizure drug Fintepla
The company did not submit certain non-clinical studies to allow the FDA to assess chronic administration of the drug.
Read More
Zogenix submits new drug application to FDA for Fintepla
Zogenix has completed its rolling submission of a New Drug Application in the US and submitted a marketing application in Europe for Fintepla for the treatment of seizures associated with Dravet syndrome.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
